- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | BofA Securities initiates coverage on Inhibikase stock with Buy rating | 6 | Investing.com | ||
| 29.12.25 | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path | 3 | Investing.com | ||
| 29.12.25 | Jefferies bekräftigt Kaufempfehlung für Inhibikase-Aktie wegen beschleunigtem FDA-Verfahren | 8 | Investing.com Deutsch | ||
| 26.12.25 | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| 26.12.25 | H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating | 3 | Investing.com | ||
| 19.12.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share | 1 | Seeking Alpha | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.11.25 | Inhibikase Therapeutics prices $100 million public offering | 1 | Investing.com | ||
| 21.11.25 | Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 20.11.25 | Inhibikase Therapeutics announces proposed public offering and pre-funded warrants | 1 | Seeking Alpha | ||
| 20.11.25 | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | 186 | GlobeNewswire (Europe) | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| 14.11.25 | Inhibikase Therapeutics GAAP EPS of -$0.13 | 2 | Seeking Alpha | ||
| 14.11.25 | Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity | 923 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 14.11.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.08.25 | Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | 413 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 14.08.25 | Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | 276 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 27.03.25 | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 529 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 196,00 | -0,31 % | Rekordquartal und AbbVie-Deal beflügeln Gubra-Aktie: Kursplus von 13,88 % | ||
| TEVA | 28,100 | -2,09 % | Teva Pharmaceutical Industries Ltd: Teva to Present at the Upcoming Investor Conferences in March | PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will... ► Artikel lesen | |
| EYEPOINT | 14,670 | 0,00 % | EyePoint Pharmaceuticals, Inc.: EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 | ||
| ORGANIGRAM GLOBAL | 1,200 | 0,00 % | Organigram Global Inc: Organigram launches Edison, Boxhot in Australia | ||
| QUANTUM BIOPHARMA | 3,080 | +1,99 % | Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) | TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 58,00 | -0,85 % | Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis | SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California... ► Artikel lesen | |
| AMARIN | 11,600 | -0,85 % | Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss | ||
| ACHIEVE LIFE SCIENCES | 3,825 | -1,16 % | Achieve Life Sciences: Entscheidet der 20. Juni über Leben und Tod? | Seit unseres Trading-Tipps im Juli letzten Jahres konnte die Aktie von Achieve Life Sciences zwischenzeitlich über +150% zulegen, korrigierte in den letzten Wochen aber wieder um mehr als 20%. Das Unternehmen... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 159,55 | -0,78 % | Jazz Pharmaceuticals Plc Q4 Profit Climbs | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million,... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,140 | -0,96 % | SELLAS LIFE SCIENCES GROUP INC zeigt strukturelle Stärke | ||
| MADRIGAL PHARMACEUTICALS | 368,80 | +0,82 % | H.C. Wainwright reiterates Madrigal Pharmaceuticals stock rating at buy | ||
| XORTX THERAPEUTICS | 0,352 | +2,62 % | XORTX Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| BRIDGEBIO PHARMA | 55,90 | -0,64 % | BridgeBio Pharma, Inc.: BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates | $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio... ► Artikel lesen | |
| OPUS GENETICS | 3,180 | -9,66 % | Opus Genetics, Inc.: Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting | Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 29,600 | 0,00 % | Rigel Pharmaceuticals: Geht es 2026 noch höher? | Die Aktie von Rigel Pharmaceuticals hatten wir sharedealsPlus-Nutzern erstmals im Jahr 2022 ans Herz gelegt. Der Kurs konnte seitdem über 400% zulegen und auch unser September-Update mit Verweis auf... ► Artikel lesen |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,060 (-2,86 %) liegt der Kurs bei 2,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.